VerImmune
Bethesda, US · Founded 2019 · Delaware corporation · 12 employees on LinkedIn · 6 known investors
Find your way into VerImmune
276 people in our graph share verified history with the VerImmune team — schools, employers, funds. One of them is your warm intro.
Deji Sasegbonunlockedknows JOSHUA WANG · together at Imperial College London (overlapped)
×2knows the team · via Imperial College London
×4knows the team · via The Johns Hopkins University
×5knows the team · via T. Rowe Price
VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.
Founders & leadership
VerImmune was founded in 2019 by JOSHUA WANG.
JW
JOSHUA WANGinFounding CEO & PresidentJoshua Wang has worked in founding and operating early-stage biotech companies with technical expertise in virology, vaccines, and immunology. He has lived and worked across Singapore, the UK, and the USA.
JT
JOHN TROYERNamed on SEC filing
Board
Investors · 6
Maryland TEDCOUpper Marlboro · $500K – $1.5M
Ulu VenturesPalo Alto · $2M
__Twitter.png)
Gaingelsreported · 2 sourcesNew York · $200K – $500K
Mana Venturesreported · 2 sourcesEstero
NuFund Venture GroupreportedSan Diego · $1M
Also in the syndicate · 1
Proxima VClead
Funding
SEC filings, press & company announcements$5.9M disclosed across 2 of 3 rounds · 2022–2024
- Undisclosed amountSeedSep 2023
Proxima VC (lead), Gaingels, Mana Ventures
Source ↗
▶$4.5MraisedSep 2024 · 6 investors · BiotechnologyRule 506(b)
▶$4.5MraisedSep 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- CYNTHIA POHDirector
- KEVIN KOH RONGSHENGDirector
- HAOLIN SUNGDirector
- CHE HSUDirector
- MARTA NEWDirector
- JOSHUA WANGExecutive Officer, Director, Promoter
- ROGER POMERANTZDirector
- Offering amount
- $8M
- Amount sold
- $4.5M
- Minimum investment
- $22.8K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.4MraisedMar 2022 · 9 investors · BiotechnologyRule 506(b)
▶$1.4MraisedMar 2022 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- ROGER POMERANTZDirector
- JOHN TROYERExecutive Officer
- CYNTHIA POHDirector
- JOSHUA WEIYUAN WANGExecutive Officer, Director, Promoter
- KEVIN KOH RONGSHENGDirector
- Offering amount
- $2.5M
- Amount sold
- $1.4M
- Minimum investment
- $25K
- Proceeds to insiders
- $125K
- First sale
- Mar 2022
- Incorporated
- Corporation, Maryland, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Infinimmune18 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.
Inimmune17 shared keywordsInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
Immuneering16 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immunomic Therapeutics14 shared keywordsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Companies competing with VerImmune for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does VerImmune do?
- VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.
- Who founded VerImmune?
- VerImmune was founded by JOSHUA WANG in 2019.
- Who are VerImmune's investors?
- VerImmune's investors include Maryland TEDCO, Ulu Ventures, Gaingels, Mana Ventures, NuFund Venture Group.
- How much funding has VerImmune raised?
- VerImmune has disclosed $5.9M raised across 2 of its 3 known rounds.
- Where is VerImmune headquartered?
- VerImmune is headquartered in Bethesda, US.